关于我们
Avenue Therapeutics, Inc. (NASDAQ: ATXI), a Fortress Biotech (NASDAQ: FBIO) Company, is a specialty pharmaceutical company.
Please be aware of Recruiting Fraud: https://www.avenuetx.com/beware-of-recruiting-fraud/
- 网站
-
https://www.avenuetx.com
Avenue Therapeutics的外部链接
- 所属行业
- 生物技术研究
- 规模
- 2-10 人
- 总部
- New York，NY
- 类型
- 上市公司
地点
-
主要
获取路线
2 Gansevoort Street
9th Floor
US，NY，New York，10014
Avenue Therapeutics员工
-
Curt Oltmans
Chief Legal Officer
-
Amy Chappell, M.D., FAAN
Strategist in Neuroscience Drug Development, Biotech CMO , Board member, and Pharma Executive
-
Faith Charles, JD
Partner at Thompson Hine LLP (Corporate & Securities) - Co-Chair of Public Companies Group, Chair Life Sciences Industry | Group Board Member
动态
-
Avenue Therapeutics announced the last patient visit in its Phase 1b/2a clinical trial of #AJ201 for the treatment of #SpinalBulbarMuscularAtrophy (#SBMA), also known as #KennedysDisease.?Topline data are expected to be reported mid-year 2024. $ATXI $FBIO For more details: https://bit.ly/4bkCari
-
Recently, Dr. Alexandra MacLean, CEO of Avenue Therapeutics, hosted Dr. Christopher Grunseich (National Institute of Neurological Disorders and Stroke) and Dr. Tahseen Mozaffar (UC Irvine) in a virtual key opinion leader event to discuss #SpinalBulbarMuscularAtrophy (#SBMA), also known as #KennedysDisease. Currently, there are no FDA approved treatments for this rare neurodegenerative disease. The event focused on the current understanding of the condition including unmet needs, and an overview of Avenue’s Phase 1/2a trial of #AJ201 for the treatment of #KennedysDisease. Click here to view a replay of the event: https://lnkd.in/e5ZiDaiW
-
Please join Avenue Therapeutics on April 4th for a virtual key opinion leader (“KOL”) event featuring Christopher Grunseich, M.D., and Tahseen Mozaffar, M.D. These industry experts will provide an overview of the spinal bulbar muscular atrophy (“SBMA”) treatment landscape and discuss the Phase 1b/2a study evaluating AJ201 in patients with SBMA, with topline data on track to read out in the second quarter of this year. Click the link to register for the event on April 4th at 11:00am EST: https://lnkd.in/e5ZiDaiW
-
-
Today, we reported our fourth quarter and full year financial results and recent corporate highlights. Read the full press release here https://lnkd.in/eEex29qR
-
Avenue is pleased to announce that Amy Chappell, M.D., FAAN will host a platform presentation of preclinical in vivo data evaluating BAER-101 at the American Society for Experimental Neurotherapeutics (ASENT) 2024 Annual Meeting today, March 13th, between 1:30-3:00pm ET. Read the full press release here https://lnkd.in/eqA8WqbC